健帆生物(300529) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥572,557,659.76, a decrease of 17.90% compared to ¥697,355,409.35 in the same period last year[6] - Net profit attributable to shareholders for Q1 2023 was ¥196,529,798.71, down 41.37% from ¥335,207,463.10 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥189,734,884.06, reflecting a 41.18% decline compared to ¥322,594,519.17 in the previous year[6] - Basic earnings per share for Q1 2023 were ¥0.25, a decrease of 40.48% from ¥0.42 in the same period last year[6] - Diluted earnings per share were ¥0.24, down 41.46% from ¥0.41 year-on-year[6] - The total profit for the current period was ¥231,678,904.69, down 41.0% from ¥393,157,424.42 in the previous period[17] - The net profit for the period was 195,250,686.39 CNY, down 41.61% from 334,390,326.17 CNY in the previous year, highlighting challenges in revenue generation[28] Cash Flow and Liquidity - The net cash flow from operating activities increased by 86.83% to ¥239,264,872.20, up from ¥128,066,902.76 in the same quarter last year[6] - The company's cash and cash equivalents increased to ¥3,084,030,612.75 from ¥2,558,755,452.52 at the beginning of the year[9] - Cash received from tax refunds rose significantly by 453.98% to ¥1,390,619.07, mainly due to an increase in software tax refunds[31] - The company reported a 259.56% increase in net cash and cash equivalents, totaling ¥535,713,372.63, attributed to new bank loans and reduced payments for construction and procurement[31] - Cash inflow from financing activities surged by 9396.94% to ¥329,199,971.04, driven by an increase in bank loans to optimize the capital structure[31] Operating Costs and Expenses - Total operating costs increased to ¥350,485,573.54, up 11.5% from ¥314,319,565.99 in the previous period[15] - Research and development expenses increased to ¥54,023,867.54, up 32.3% from ¥40,771,649.13 in the previous period[15] - Sales expenses rose to ¥156,935,831.02, an increase of 26.1% from ¥124,425,157.36 in the previous period[15] - The company reported a financial expense of -¥8,708,659.80, compared to a financial income of ¥957,753.62 in the previous period[15] - The company experienced a 1009.28% increase in financial expenses, resulting in a loss of -8,708,659.80 CNY, primarily due to increased interest income from deposits[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 64,574, with the largest shareholder holding 43.97% of the shares[33] - The largest shareholder, Dong Fan, holds 355,131,867 shares, representing 43.97% of the total shares[33] - The total number of restricted shares held by major shareholders at the end of the period was approximately 292.79 million shares[36] Challenges and Strategic Focus - The company faced challenges due to rising production costs and a higher sales proportion of blood purification equipment, leading to a decline in gross margin[39] - R&D and sales expenses increased year-on-year, contributing to the significant drop in net profit[39] - The company continues to invest in R&D and market promotion to support future growth[39]